Select a community
HIV
Find out more about the PatientsLikeMe
HIV Community
Home > Community Treatment Reports > Combivir/Nevirapine Treatment Report
What is Combivir/Nevirapine?

This is a combination of the antiretroviral drug Combivir (a combination of lamivudine and zidovudine (AZT), and Nevirapine (brand name Viramune). This combination may simplify your therapy and reduce the rate of developing resistance to the separate drugs. Read more...Click to read more below

Reasons taken & Efficacy

Reasons and Efficacy
Reasons taken # of patients Major Moderate Slight None Can’t tell # of patients evaluated by
Treat my HIV 9 1
Swollen glands 1 0
Other 1 0

Mouse over the table for more information

Side Effects

Side effects as an overall problem

Severe
0 0%
Moderate
1 100%
Mild
0 0%
None
0 0%

Most commonly reported side effects

Numbness in feet
1 100%
Peripheral Neuropathy
1 100%
  • Mild
  • Moderate
  • Severe

Dosages

  daily 2 daily 2 tbs. daily 20 mg daily 40 mg daily 150 mg daily 400 mg daily
  1 Number of Patients: 1 2 Number of Patients: 2 2 Number of Patients: 2 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1  

Stop Reasons

Why Patients Stopped Taking Combivir/Nevirapine (multiple reasons could be selected)
Reason # Patients Percentage of patients
Doctor's advice
2 67% Doctor's advice: 67%
Expense
1 33% Expense: 33%
Personal research
1 33% Personal research: 33%
Side effects too severe
1 33% Side effects too severe: 33%
Other
1 33% Other: 33%

See all 3 patients who’ve stopped taking Combivir/Nevirapine

Currently Taking Combivir/Nevirapine

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
1
0
1

Stopped Taking Combivir/Nevirapine

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0
2

Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Always
1 100%
Usually
0 0%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Very
0 0%
Somewhat
0 0%
A little
1 100%
Not at all
0 0%

Cost

Paid out of pocket

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
0 0%
< $25
1 100%

Report created on November 21, 2009.